



POLICIES AND PROCEDURE MANUAL

Policy: MBP 340.0

Section: Medical Benefit Pharmaceutical Policy

Subject: PiaSky (crovalimab-akkz)

Applicable line of business:

Commercial	X	Medicaid	X
Medicare	X	ACA	X
CHIP	X		

I. Policy:

PiaSky (crovalimab-akkz)

II. Purpose/Objective:

To provide a policy of coverage regarding PiaSky (crovalimab-akkz).

III. Responsibility:

- A. Medical Directors
- B. Medical Management
- C. Pharmacy Department

IV. Required Definitions

1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy.
2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy.
3. Devised – the date the policy was implemented.
4. Revised – the date of every revision to the policy, including typographical and grammatical changes.
5. Reviewed – the date documenting the annual review if the policy has no revisions necessary.

V. Additional Definitions

Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are:

- a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury;
- b. provided for the diagnosis and the direct care and treatment of the Member's condition, illness disease or injury;
- c. in accordance with current standards good medical treatment practiced by the general medical community;

Commercial

Geisinger Health Plan may refer collectively to health care coverage sponsors Geisinger Health Plan, Geisinger Quality Options, Inc., and Geisinger Indemnity Insurance Company, unless otherwise noted. Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

Medicare

Geisinger Gold Medicare Advantage HMO, PPO, and HMO D-SNP plans are offered by Geisinger Health Plan/Geisinger Indemnity Insurance Company, health plans with a Medicare contract. Continued enrollment in Geisinger Gold depends on contract renewal. Geisinger Health Plan/Geisinger Indemnity Insurance Company are part of Geisinger, an integrated health care delivery and coverage organization.

CHIP

Geisinger Health Plan Kids (GHP Kids) is a Children's Health Insurance Program (CHIP) offered by Geisinger Health Plan in conjunction with the Pennsylvania Department of Human Services (DHS). Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

Medicaid

Geisinger Health Plan Family (GHP Family) is a Medical Assistance (Medicaid) insurance program offered by Geisinger Health Plan in conjunction with the Pennsylvania Department of Human Services (DHS). Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

- d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and
- e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient

Medicaid Business Segment

Medically Necessary — A service, item, procedure, or level of care compensable under the Medical Assistance program that is necessary for the proper treatment or management of an illness, injury, or disability is one that:

- i. Will, or is reasonably expected to, prevent the onset of an illness, condition, injury or disability.
- ii. Will, or is reasonably expected to, reduce or ameliorate the physical, mental or developmental effects of an illness, condition, injury or disability.
- iii. Will assist the Member to achieve or maintain maximum functional capacity in performing daily activities, taking into account both the functional capacity of the Member and those functional capacities that are appropriate for Members of the same age.

DESCRIPTION:

PiaSky (crovalimab-akkz) is a humanized monoclonal antibody directed against complement C5. It binds specifically and with high affinity to the complement protein C5, inhibiting cleavage into C5a and C5b to prevent formation of the membrane attack complex (MAC) and inhibit terminal complement-mediated intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria. Crovalimab utilizes an anti-C5 sequential monoclonal antibody recycling technology to prolong half-life and bioavailability.

CRITERIA FOR USE: Requires Prior Authorization by Medical Director or Designee

PiaSky (crovalimab-akkz) will be considered medically necessary for the commercial, exchange, CHIP, and Medicaid lines of business when all of the following criteria are met:

- Medical record documentation of a diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) **AND**
 - Physician provided documentation of flow cytometry confirming diagnosis **AND**
 - Physician provided documentation that PiaSky is prescribed by a hematologist **AND**
 - Physician provided documentation of the insured individual being vaccinated with the meningococcal vaccine **AND**
 - Physician documentation of one of the following:
 - Member is transfusion-dependent (i.e., has at least 1 transfusion in the 24 months prior to initiation of crovalimab due to documented hemoglobin less than 7 g/dL in persons without anemic symptoms or less than 9 g/dL in persons with symptoms from anemia) prior to initiation of crovalimab treatment **OR**
 - There is a significant adverse impact on the insured individual's health such as end organ damage or thrombosis without other cause.
- AND**
- Medical record documentation of therapeutic failure on, intolerance to, or contraindication to the preferred eculizumab product

AUTHORIZATION DURATION: Approval will be given for 6 months. Additional coverage will only be provided when documentation of the following is provided:

- Member requires fewer transfusions or has stabilization of Hb levels **AND**
- Reduction in intravascular hemolysis as evidenced reduction in elevated LDH levels from baseline **AND**
- No recurrent infections

Note: For Medicaid (GHP Family), any requests for services that do not meet criteria set in the PARP will be evaluated on a case-by-case basis.

PiaSky (crovalimab-akkz) will be considered medically necessary for the Medicare line of business when all of the following criteria are met:

- Medical record documentation of a diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) **AND**
- Physician provided documentation of flow cytometry confirming diagnosis **AND**
- Physician provided documentation that PiaSky is prescribed by a hematologist **AND**
- Physician provided documentation of the insured individual being vaccinated with the meningococcal vaccine **AND**
- Physician documentation of one of the following:
 - Member is transfusion-dependent (i.e., has at least 1 transfusion in the 24 months prior to initiation of crovalimab due to documented hemoglobin less than 7 g/dL in persons without anemic symptoms or less than 9 g/dL in persons with symptoms from anemia) prior to initiation of crovalimab treatment **OR**
 - There is a significant adverse impact on the insured individual's health such as end organ damage or thrombosis without other cause.

AUTHORIZATION DURATION: Approval will be given for 6 months. Additional coverage will only be provided when documentation of the following is provided:

- Member requires fewer transfusions or has stabilization of Hb levels **AND**
- Reduction in intravascular hemolysis as evidenced reduction in elevated LDH levels from baseline **AND**
- No recurrent infections

LINE OF BUSINESS:

Eligibility and contract specific benefit limitations and/or exclusions will apply. Coverage statements found in the line of business specific benefit document will supersede this policy.

REFERENCES:

1. PiaSky [Prescribing Information]. South San Francisco, CA. Genentech, Inc. June 2024.

This policy will be revised as necessary and reviewed no less than annually.

Devised: 3/11/25

Revised:

Reviewed:

MA UM Committee approval: 4/29/25

DHS PARP approval: 4/4/25